We propose that compounds that modulate the deubiquitinase activity of either USP33 or STAMBP may be of therapeutic use in the treatment of neuroendocrine tumors that result from impaired GCGR trafficking and signaling. Here, GCGR is linked to neuroendocrine neoplasm.